Please enable Javascript
Renal Cell Carcinoma Diagnostics
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
Drs. Beckermann, Rathmell, and Bacigalupa continue their discussion on the therapeutic potential of inhibiting ACSS2 including how blocking ACSS2 may affect immune cells in the tumor microenvironment. Find their previous comments here. ...
View More
Advertisement
Targeting ACSS2 to Regulate HIF-2α Stability and Suppress ccRCC Growth
Jeffrey Rathmell, PhD
Renal Cell Carcinoma Diagnostics
|
July 26, 2024
Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
Genomic Study of Fumarate Hydratase-Deficient RCC
Katy Marshall
Renal Cell Carcinoma Diagnostics
|
July 16, 2024
Researchers evaluated the tissue samples of 126 treatment-naïve patients collected from a multicenter database.
15-Gene Signature for Predicting Clear Cell Renal Cell Carcinoma Risk
Daniel Joyce, MD
Renal Cell Carcinoma Diagnostics
|
July 9, 2024
Dr. Simpa Salami's research into a 15-gene prognostic signature for predicting ccRCC risk is discussed in this interview.
Analyzing the Effects of ACSS2 on Cancer Cell Growth in Patients With ccRCC
Katy Marshall
Renal Cell Carcinoma Diagnostics
|
June 27, 2024
ACSS2 inhibition led to lowered chromatin accessibility, HIF-2α expression, and stability.
Safety Considerations for 89Zr-girentuximab PET/CT Imaging in ccRCC
Rana McKay, MD
Renal Cell Carcinoma Diagnostics
|
June 25, 2024
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
15-Gene Signature Predicts RFS, DFS in Patients With ccRCC
Emily Menendez
Renal Cell Carcinoma Diagnostics
|
June 21, 2024
The signature has been initially validated to improve ccRCC risk stratification and provide better treatment allocation.
Measuring the Radiation Exposure Risk of 89Zr for PET/CT Imaging
Emily Menendez
Renal Cell Carcinoma Diagnostics
|
June 25, 2024
The use of 89Zr PET/CT and subsequent surgery in patients treated with it demonstrated low radiation exposure levels.
Plasma KIM-1 as a Preoperative Biomarker for RCC
Wenxin Xu, MD
Renal Cell Carcinoma Diagnostics
|
May 28, 2024
Drs. Xu and Joyce explain the rationale behind recent research on plasma KIM-1, its significance as a biomarker, and more.
Plasma KIM-1, Intervention Versus Surveillance in Patients With RCC
Emily Menendez
Renal Cell Carcinoma Diagnostics
|
May 15, 2024
Kidney injury molecule-1 is a transmembrane protein that can serve as a urinary indicator of acute renal tubular injury.
Patient Selection, Counseling, and Improved Biomarkers, Imaging: Moving Forward From KEYNOTE-564
Sarah Psutka, MD, MSc
Renal Cell Carcinoma Diagnostics
|
May 7, 2024
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
View More
Advertisement
Video Insights
1
2
3
4
5
6
EV-302 Patient-Reported Outcomes
July 16, 2024
15-Gene Signature for Predicting Clear Cell Renal Cell Carcinoma Risk
July 9, 2024
Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting
July 8, 2024
Sequential Endoluminal Chemotherapy for Non-Invasive High-Grade UTUC
June 26, 2024
Watch More
Conferene Coverage
Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting
Vishnu Murthy
CRPC
|
July 8, 2024
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Safety Considerations for 89Zr-girentuximab PET/CT Imaging in ccRCC
Rana McKay, MD
Renal Cell Carcinoma Diagnostics
|
June 25, 2024
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
SNMMI 2024: Dosimetry of 177Lu-PSMA RLTs, FLEX-MRT, and More
Jérémie Calais, MD, PhD
RLT
|
June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting
Jérémie Calais, MD, PhD
RLT
|
June 20, 2024
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC
Oliver Sartor, MD
RLT
|
June 18, 2024
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC
Geoffrey Johnson, MD, PhD
RLT
|
June 17, 2024
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
View More
Knowledge Hub Spotlight
Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Localized Renal Cell Carcinoma
nccRCC
Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Localized Renal Cell Carcinoma
nccRCC
Advertisement
Section Editor
Daniel Joyce, MD
Department of Urology | Vanderbilt University Medical Center
Advertisement
Get the latest RCC research straight to your inbox.
Subscribe Now